Investigational Drug Information for PF-07081532
✉ Email this page to a colleague
What is the development status for investigational drug PF-07081532?
PF-07081532 is an investigational drug.
There have been 11 clinical trials for PF-07081532.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 8th 2022.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Overweight. The leading clinical trial sponsors are Pfizer and [disabled in preview].
There are two US patents protecting this investigational drug and twenty-seven international patents.
Summary for PF-07081532
| US Patents | 2 |
| International Patents | 27 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 1 (2022-11-08) |
| Vendors | 7 |
Recent Clinical Trials for PF-07081532
| Title | Sponsor | Phase |
|---|---|---|
| A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants | Pfizer | Phase 1 |
| A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults | Pfizer | Phase 1 |
| A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese | Pfizer | Phase 1 |
Clinical Trial Summary for PF-07081532
Top disease conditions for PF-07081532
Top clinical trial sponsors for PF-07081532
US Patents for PF-07081532
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-07081532 | ⤷ Subscribe | GLP-1 receptor agonists and uses thereof | Pfizer Inc. (New York, NY) | ⤷ Subscribe |
| PF-07081532 | ⤷ Subscribe | GLP-1 receptor agonists and uses thereof | Pfizer Inc. (New York, NY) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-07081532
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-07081532 | Argentina | AR114967 | 2038-06-13 | ⤷ Subscribe |
| PF-07081532 | Australia | AU2019285491 | 2038-06-13 | ⤷ Subscribe |
| PF-07081532 | Brazil | BR112020024470 | 2038-06-13 | ⤷ Subscribe |
| PF-07081532 | Canada | CA3045644 | 2038-06-13 | ⤷ Subscribe |
| PF-07081532 | Chile | CL2020003222 | 2038-06-13 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
